Kolexia
Laribi Kamel Biologie médicale
Laribi Kamel
Biologie médicale
Centre Hospitalier du Mans
Le Mans, France
270 Activités
1.3 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Lymphomes Leucémie chronique lymphocytaire à cellules B Leucémie lymphoïde Syndromes myélodysplasiques Myélome multiple Leucémie aigüe myéloïde Leucémie myéloïde Lymphome B

Collaborateurs

Voir plus
Tournilhac Olivier
Tournilhac Olivier
Hôpital Estaing, Clermont-Ferrand, France
Ysebaert Loic
Ysebaert Loic
Oncopole Toulouse, Toulouse, France
Feugier Pierre
Feugier Pierre
Hôpital Brabois, Vandoeuvre-lès-Nancy, France
Dartigeas Caroline
Dartigeas Caroline
Centre hospitalier de Tours, Tours, France

Industries

Voir plus
BEIGENE
22 collaboration(s)
Dernière en 2023
Abbvie
16 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
16 collaboration(s)
Dernière en 2023
Novartis
15 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
RHUMM: Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma RHU(M)M Random or H24 Urine in (Multiple) Myeloma
Essai Clinique (Intergroupe Francophone du Myélome)   15 mars 2024
A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy: A Phase 3 Multicenter, Open-label, Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
Essai Clinique (Astellas)   07 mars 2024
CALR-mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM.
American journal of hematology   25 février 2024
BRUIN-CLL-314: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)
Essai Clinique (Loxo Oncology, Inc.)   24 janvier 2024
BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Essai Clinique (Loxo Oncology, Inc.)   24 janvier 2024
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome: A Phase II Study of Venetoclax in Combination With 10-Day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia and Relapsed High-Risk Myelodysplastic Syndrome and Blastic Plasmacytoid Dendritic Cell Neoplasm
Essai Clinique (M.D. Anderson Cancer Center)   03 janvier 2024
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA: A Randomized Phase I/ II Multicenter Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Essai Clinique (Celgene)   02 janvier 2024
Real-life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study.
EJHaem   13 décembre 2023
Study of Lacutamab in Peripheral T-cell Lymphoma: A Randomized Non Comparative Phase II Study of Lacutamab With GemOx Versus GemOx Alone in Relapsed/Refractory Patients With Peripheral T-cell Lymphoma
Essai Clinique (Innate Pharma)   04 décembre 2023
Cytopénies auto-immunes associées aux hémopathies lymphoïdes B indolentes : une étude de cohorte multicentrique française
87e CONGRÈS FRANÇAIS DE MÉDECINE INTERNE   01 décembre 2023